$-0.11
(Market cap
$16,496 Mln
Revenue (TTM)
$8,838 Mln
P/E Ratio
20.5
P/B Ratio
2.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
15.8
-
Debt to Equity
0.9
-
Book Value
$--
-
EPS
$4.2
-
Face value
--
-
Shares outstanding
613,934,040
10 Years Aggregate
CFO
$24,654.60 Mln
EBITDA
$30,917.84 Mln
Net Profit
$24,512.58 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
| -13.6 | -0.2 | -9.6 | 25.0 | -13.2 | -8.0 | 4.2 |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
| 47.6 | -34.2 | -24.9 | 7.1 | -2.7 | 82.1 | 36.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
|
26.6 | 16,496.4 | 8,837.9 | 2,614.3 | 36.5 | 45.7 | 20.5 | 2.9 |
| 3.6 | 352.1 | 68.1 | -67.3 | -104.0 | -83.9 | -- | 5.9 | |
| 18.8 | 1,075.9 | 0.0 | -167.9 | -- | -128.7 | -- | 5.2 | |
| 27.7 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 4.0 | 156.8 | 0.0 | -72.1 | -- | -88 | -- | 1.8 | |
| 13.7 | 889.9 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.3 | 3.3 | |
| 3.4 | 536.4 | 4.0 | -198.4 | -5,037.7 | -166.3 | -- | 7.0 | |
| 6.7 | 292.9 | 0.8 | -75.0 | -8,478.9 | -121.5 | -- | 5.9 | |
| 6.5 | 562.3 | 156.3 | -138.0 | -16.7 | -121.5 | -- | 6.3 | |
| 18.5 | 2,090.9 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Genmab A/S ADS - ADR
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R)... diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Address: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 Read more
-
Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
-
Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
-
Headquarters
Copenhagen
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Genmab A/S ADS - ADR
What is the current share price of Genmab A/S ADS - ADR Today?
The share price of Genmab A/S ADS - ADR is $26.60 (NASDAQ) as of 28-May-2026 12:37 EDT. Genmab A/S ADS - ADR has given a return of -13.16% in the last 3 years.
What is the current PB & PE ratio of Genmab A/S ADS - ADR?
The P/E ratio of Genmab A/S ADS - ADR is 20.51 times as on 22-May-2026.
The P/B ratio of Genmab A/S ADS - ADR is 2.90 times as on 22-May-2026, a 44 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
20.04
|
3.31
|
|
2024
|
1.72
|
0.37
|
|
2023
|
4.82
|
0.66
|
|
2022
|
5.13
|
1.03
|
|
2021
|
8.83
|
1.18
|
What is the 52 Week High and Low of Genmab A/S ADS - ADR?
The 52-week high and low of Genmab A/S ADS - ADR are Rs 34.68 and Rs 20.23 as of 28-May-2026.
What is the market cap of Genmab A/S ADS - ADR?
Genmab A/S ADS - ADR has a market capitalisation of $ 16,496 Mln as on 22-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Genmab A/S ADS - ADR?
Before investing in Genmab A/S ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.